Hingmire, S., & Raut, N. (2015). Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens. South Asian Journal of Cancer, 4, 7–10.
To assess the safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting (CINV) prophylaxis with highly emetogenic cheomtherapy (HEC) or moderately emetogenic chemotherapy (MEC) regimens
Patients received 125 mg aprepitant on day 1 and 80 mg along with palonosetron and dexamethasone
PHASE OF CARE: Active antitumor treatment
Open-label, prospective, observational
For all regimens, CR rates were 96.8%, 93.7%, and 92% for acute, delayed, and overall phases. Nine percent reported side effects; the most common was hiccoughs.
Triple drug antiemetic prophylaxis was effective to manage CINV in most patients.
This study adds to the substantial body of evidence for the efficacy of triple drug antiemetic regimens for the prevention of CINV.